CNNMoney.com
Companies Economy International Corrections Pre-market Trading After-hours Trading Winners/Losers/Actives Bonds Currencies Commodities World Markets Money Magazine Real Estate Taxes Jobs Ask the Expert Money 101 Autos Mutual Funds The Help Desk Loan Center Best Places to Live Ask the Expert Ultimate Guide to Retirement Retirement Calculators Best Funds Best Places to Retire Fortune Brainstorm Tech Apple 2.0 Blog Big Tech Blog Sectors and Stocks Tech Talk Resource Guide Small Business Makeovers Questions & Answers Small Business Video 100 Best Places to Launch FSB 100 Fortune Small Business Fortune 500 Brainstorm Tech Investing Management C-Suite Rankings Main Create Portfolio Edit Portfolio Create Alerts Edit Alerts
'Morning-after' pill wins key FDA approval
Barr Pharmaceuticals says regulators approve non-prescription sale of Plan B emergency contraception.

NEW YORK (CNNMoney.com) -- Barr Pharmaceuticals said Thursday the Food and Drug Administration approved the over-the-counter sale of its "morning-after" pill.

The approval gives women 18 years and older non-prescription access to the Plan B emergency contraception pill. Women 17 years and younger still will need a prescription, the company said.

fda_food_and_drug.03.jpg
barr.mkw.gif

Plan B is made by Duramed Pharmaceuticals Inc., a subsidiary of Barr Pharmaceuticals.

Shares of Barr Pharmaceuticals (Charts) rose 1.2 percent in early Wall Street trading on the approval.

"While we still feel that Plan B should be available to a broader age group without a prescription, we are pleased that the Agency has determined that Plan B is safe and effective for use by those 18 years of age and older as an over-the-counter product," Barr CEO Bruce Downey said a statement.

Plan B, an emergency oral contraceptive that can prevent pregnancy if taken within 72 hours after intercourse, has been sold as a prescription drug since FDA approval in 1999.

But it has faced difficulties winning approval for over-the-counter sales.

In 2003, the FDA's advisory panel voted 24 to 3 in favor of OTC status, but the agency did not follow the advice of its panel, as it usually does, and later denied OTC status.


More breaking business headlines Top of page

YOUR E-MAIL ALERTS
Follow the news that matters to you. Create your own alert to be notified on topics you're interested in.

Or, visit Popular Alerts for suggestions.
Manage alerts | What is this?
© 2009 Cable News Network. A Time Warner Company. All Rights Reserved. Terms under which this service is provided to you. Privacy Policy
Copyright © 2009 BigCharts.com Inc. All rights reserved. Please see our Terms of Use.
MarketWatch, the MarketWatch logo, and BigCharts are registered trademarks of MarketWatch, Inc.
Intraday data provided by Interactive Data Real-Time Services and subject to the Terms of Use.
Intraday data is at least 20-minutes delayed. All times are ET.
Historical, current end-of-day data, and splits data provided by Interactive Data Pricing and Reference Data.
Fundamental data provided by Morningstar, Inc..
SEC Filings data provided by Edgar Online Inc..
Earnings data provided by FactSet CallStreet, LLC.